This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company’s biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.
Features and benefits
Highlights
Harvest Moon specializes in the development of complex generics and biosimilars. These products are in-licensed from emerging market copy-biologic developers before they are out-licensed to partners in developed markets, with Harvest Moon’s receiving royalties. Harvest Moon has 30 biosimilar products in various stages of development.
Your key questions answered
Released On: 9/3/2012
Views: 3179
Released On: 8/31/2012
Views: 3906
Released On: 8/27/2012
Views: 2192
Released On: 8/23/2012
Views: 3046
Released On: 8/23/2012
Views: 2074
Released On: 8/21/2012
Views: 2770
Released On: 8/16/2012
Views: 3403
Released On: 8/16/2012
Views: 2021
Released On: 8/16/2012
Views: 4270
Released On: 8/14/2012
Views: 2155
Released On: 8/14/2012
Views: 1849